tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Heron Therapeutics reports Q3 EPS (17c), consensus (29c)

Reports Q3 revenue $31.43M, consensus $32.65M. Craig Collard, CEO, commented, “In just six months of initiating our corporate restructuring plan, I am pleased to announce its near completion. The enhanced clarity in our sales projections and operational visibility brings optimism for our path to profitability. I am delighted to offer this quarterly update on our expectations for the Q4 and to unveil our 2024 guidance. Heron is now strategically positioned to deliver substantial value in the coming years, boasting a robust balance sheet, a dedicated management team, and a steadfast commitment to operational excellence.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on HRTX:

Disclaimer & DisclosureReport an Issue

1